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Abstract
Background: A low incidence of breast cancer in the Mediterranean basin suggests that a high
consumption of Extra Virgin Olive Oil (EVOO) might confer this benefit. While the anti-HER2
oncogene effects of the main ω-9 fatty acid present in EVOO triacylglycerols (i.e., oleic acid) have
been recently described, the anti-breast cancer activities of EVOO non-glyceridic constituents -
which consist of at least 30 phenolic compounds-, remained to be evaluated.
Methods:  Semi-preparative HPLC was used to isolate EVOO polyphenols (i.e., tyrosol,
hydroxytyrosol, oleuropein). Both the anti-proliferative and the pro-apoptotic effects of EVOO
phenolics were evaluated by using MTT-based quantification of metabolically viable cells and ELISA-
based detection of histone-associated DNA fragments, respectively. The nature of the interaction
between oleuropein aglycone and the anti-HER2 monoclonal antibody trastuzumab (Herceptin™)
was mathematically evaluated by the dose-oriented isobologram technique. HER2-specific ELISAs
were employed to quantitatively assess both the basal cleavage of the HER2 extracellular domain
(ECD) and the expression level of total HER2. The activation status of HER2 was evaluated by
immunoblotting procedures using a monoclonal antibody specifically recognizing the tyrosine
phosphorylated (Phosphor-Tyr1248) form of HER2.
Results: Among EVOO polyphenols tested, oleuropein aglycone was the most potent EVOO
phenolic in decreasing breast cancer cell viability. HER2 gene-amplified SKBR3 cells were ~5-times
more sensitive to oleuropein aglycone than HER2-negative MCF-7 cells. Retroviral infection of the
HER2 oncogene in MCF-7 cells resulted in a "SKBR3-assimilated" phenotype of hypersensitivity to
oleuropein aglycone. An up to 50-fold increase in the efficacy of trastuzumab occurred in the
presence of oleuropein aglycone. A preclinical model of acquired autoresistance to trastuzumab
(SKBR3/Tzb100 cells) completely recovered trastuzumab sensitivity (> 1,000-fold sensitization)
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when co-cultured in the presence of oleuropein aglycone. Indeed, the nature of the interaction
between oleuropein aglycone and trastuzumab was found to be strongly synergistic in Tzb-resistant
SKBR3/Tzb100 cells. Mechanistically, oleuropein aglycone treatment significantly reduced HER2
ECD cleavage and subsequent HER2 auto-phosphorylation, while it dramatically enhanced Tzb-
induced down-regulation of HER2 expression.
Conclusion: Olive oil's bitter principle (i.e., oleuropein aglycone) is among the first examples of
how selected nutrients from an EVOO-rich "Mediterranean diet" directly regulate HER2-driven
breast cancer disease.
Background
The growing popularity of the Mediterranean diet is due
to a large body of epidemiological studies showing how
the incidence of certain cancers is the lowest in the Medi-
terranean basin. It has been suggested that this is largely
due to the relatively safe and even protective dietary habits
of this area [1-9]. Olive oil is an integral ingredient of the
traditional Mediterranean diet and several studies
attribute many of the healthy advantages of this diet to
olive oil's unique characteristics. Indeed, the relationship
between the intake of olive oil and cancer risk has become
a controversial issue that could have very important reper-
cussions in human health as it may have a potential role
in lowering the risk of some human neoplasms [4,7-9].
Thus, different studies have shown that the consumption
of olive oil have a potential protective effect towards sev-
eral malignancies, especially breast cancer (stomach,
ovary, colon and endometrium cancer too). However, the
final proof about the specific mechanisms by which the
different components of olive oil exert their potential pro-
tective effects on the promotion and progression of
human cancers requires further investigations.
Peculiar to olive oil is the abundance of the ω-9 MUFA
oleic acid (OA; 18:1n-9), which ranges from 56% to 84%
of total FAs, while ω-6 linoleic acid (18:2n-6), the major
essential FA and the most abundant polyunsaturated FA
(PUFA) in our diet, is present in concentrations between
7 and 10%. Although a single FA cannot longer be consid-
ered as an independent indicator of cancer risk, olive oil
appears to unite a new composite biomarker of a low risk
for breast cancer and, probably, for other types of human
cancer, i.e., a low ω-6/ω-3 PUFA ratio and elevated ω-9
MUFA levels [10,11]. Besides this very favorable fat com-
position, the other fundamental characteristic of this oil is
the presence of a large number of phenolic compounds
including simple phenols (e.g., tyrosol, hydroxytyrosol,
and elenolic acid), lignans (e.g., pinoresinol and acetox-
ypinoresinol) and secoiridoids (e.g., deacetoxy oleuro-
pein aglycone, oleuropein aglycone and ligstroside
aglycone) [12-18]. The effects of ω-9 MUFAs such as OA
on cancer etiology and progression are still somewhat
controversial as some epidemiological studies have
revealed that intake of OA sources, particularly olive oil,
appears to be protective against several carcinomas,
whereas research in experimental animals has yielded
inconsistent results, having reported a non-promoting or
low-promoting effect to a protective one. On the other
hand, little is known about the anti-cancer effects, if any,
of the phenolics compounds found in olives and olive-
derived products such as olive oil. Therefore, one of the
remaining concerns -before going for a causal interpreta-
tion of the inverse relationship between olive oil intake
and cancer risk- is to definitely establish whether olive oil-
related anti-cancer effects can be explained through either
the ω-9 MUFA content (i.e., OA) or the phenolic compo-
nents of the unsaponifiable fraction.
Since cancer development and progression is believed to
be a multi-step process, we recently designed a systematic
approach aimed to understand the ultimate molecular
mechanisms of how key cancer-related oncogenes can be
regulated by olive oil's components using human cancer-
derived in vitro models. Our findings revealed that exoge-
nous supplementation of cultured cancer cells with phys-
iological concentrations of the ω-9 MUFA OA drastically
suppressed the expression and activity of HER2 (erbB-2)
[9,11,19-21], one of the most commonly analyzed proto-
oncogenes in human cancer studies as it plays a pivotal
role in oncogenic transformation, tumorigenesis and
metastasis [22-25]. Patients with HER2-overexpressing
cancer are associated with unfavorable prognosis, shorter
relapse time, and low survival rate [26,27]. These findings
generated intense public interest, since no toxicities have
been reported or suspected with OA, and suggested that
supplementation with olive oil may represent a promising
dietary intervention for the prevention and/or manage-
ment of HER2-related carcinomas [28,29]. However, from
the standpoint of molecular nutrition, a food such as olive
oil cannot be considered as a drug where the active com-
pound is concentrated and formulated in an optimal way
to exert its activity. Thus, though there is no longer any
doubt that olive oil has the potential to actively modulate
cancer disease, it should be stressed that olive oil must be
considered using a broader approach considering all the
components present and not only a single one [30-34].BMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
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Here, we evaluated the anti-cancer contribution of indi-
vidual olive oil's phenolic compounds [31-34]. Four rep-
resentative phenolics (i.e., tyrosol, hydroxytyrosol,
oleuropein aglycone and oleuropein glycoside) isolated
from extra virgin olive oil (EVOO) -the juice of the olive
obtained solely by pressing- were characterized for their
abilities to affect breast cancer cell growth and survival,
HER2 oncogene expression and activity and efficacy of
HER2 oncogene-targeting therapies.
Methods
Agents
Oleuropein glycoside was obtained from Extrasynthèse
(Genay, France). Tyrosol, hydroxytyrosol, oleuropein
aglycone and elenolic acid were isolated from EVOO (Ber-
tolli, Unilever Bestfoods Italia S.p.A., Inveruno-MI, Italy)
by semi-preparative reverse-phase high performance liq-
uid chromatography [Alegria Carrasco Pancorbo, Rocio
Garcia Villalba, Alejandro-Vazquez Martin, Javier A.
Menendez, Alberto Fernandez Gutierrez, Antonio Segura
Carretero."Isolation and characterization of polyphenols
from polar extracts of VOO using HPLC or EC and mass
spectrometry" (Manuscript in preparation)]. Trastuzumab
(Herceptin™) was provided by Hospital Universitario de
Girona Dr. Josep Trueta Pharmacy (Girona, Spain), solu-
bilized in bacteriostatic water for injection containing
1.1% benzyl alcohol (stock solution at 21 mg/ml), stored
at 4°C and used within one month. Tyrosol, hydroxytyro-
sol, oleuropein aglycone and elenolic acid were dissolved
in 100% ethanol (stock solutions at 10 mM) and stored at
-80°C until use. Oleuropein glycoside was dissolved in
bacteriostatic water (stock solution at 10 mM) and stored
at -80°C until use. For experimental use, EVOO phenolics
and trastuzumab and were prepared freshly from stock
solutions and diluted with growth medium. Control cells
were cultured in medium containing the same concentra-
tion (v/v) as the experimental cultures with treatments.
The vehicle solutions had no noticeable influence on the
proliferation of experimental cells.
Cell lines and culture conditions
MCF-7 breast cancer cells were obtained from the Ameri-
can Type Culture Collection (ATCC) and they were rou-
tinely grown in Dulbecco's modified Eagle's medium
(DMEM, Gibco) containing 10% heat-inactivated foetal
bovine serum (FBS, Bio-Whittaker), 1% L-glutamine, 1%
sodium pyruvate, 50 U/ml penicillin and 50 μg/ml strep-
tomycin. SKBR3 breast cancer cells were obtained from
Dr. H. Riese (Centro Nacional de Biotecnología -CNB-,
Madrid, Spain) and they were passaged in McCoy's 5 A
medium (Gibco) containing 10% heat-inactivated FBS,
1% L-glutamine, 1% sodium pyruvate, 50 U/ml penicillin
and 50 μg/ml streptomycin. Cells were maintained at
37°C in a humidified atmosphere of 95% air/5% CO2.
Cells were screened periodically for Mycoplasma contami-
nation.
Construction of pBABE/HER2 retroviruses and retroviral 
infection
A full-length human HER2 cDNA construct in the pCMV-
SPORT6 plasmid was purchased from RZPD (Berlin, Ger-
many). The insert was excised from pCMV-SPORT6 using
EcoRV and NotI sites and blunt end ligated into the
pBABE-puro retroviral vector (Addgene) at the EcoRI site.
Retroviruses were generated by co-transfection of 293T-
derived phoenix cells with the retroviral constructs
(pBABE, pBABE-HER2) and the packaging vector pCL-Eco
by using FuGene transfection reagent (Roche Diagnostics,
Barcelona, Spain) and 5 μg of each plasmid per 0.5 × 106
cells. 293T cells were cultured at 5% CO2, 37°C in DMEM
containing 10% (v/v) heat-inactivated FBS. After 48 h,
medium conditioned by transfected 293T cells was fil-
tered and immediately added to MCF-7 cells. At 48 h fol-
lowing infection, MCF-7/HER2 cells were selected by
using 2 μg/ml puromycin for 72 h. Expression of virally
encoded HER2 protein was confirmed by HER2-specific
ELISA analyses (see below).
Metabolic status assessment (MTT-based cell viability 
assays)
The ability of EVOO phenolic compounds to affect breast
cancer cell viability was determined using a standard
colorimetric MTT (3–4, 5-dimethylthiazol-2-yl-2, 5-
diphenyl-tetrazolium bromide) reduction assay. Cells in
exponential growth were harvested by trypsinization and
seeded at a concentration of ~2.5 × 103 cells/200 μl/well
into 96-well plates, and allowed an overnight period for
attachment. Then the medium was removed and fresh
medium along with various concentrations of EVOO phe-
nolics, trastuzumab or combinations of compounds as
specified, were added to cultures in parallel. Agents were
studied in combination concurrently. Control cells with-
out agents were cultured using the same conditions with
comparable media changes. Compounds were not
renewed during the entire period of cell exposure. Follow-
ing treatment (5 days), the medium was removed and
replaced by fresh drug-free medium (100 μl/well), and
MTT (5 mg/ml in PBS) was added to each well at a 1/10
volume. After incubation for 2–3 hr at 37°C, the superna-
tants were carefully aspirated, 100 μl of DMSO were
added to each well, and the plates agitated to dissolve the
crystal product. Absorbances were measured at 570 nm
using a multi-well plate reader (Model Anthos Labtec
2010 1.7 reader). The cell viability effects from exposure
of cells to each compound alone and their combination
were analyzed as percentages of the control cell absorb-
ances, which were obtained from control wells treated
with appropriate concentrations of the compounds vehi-
cles that were processed simultaneously. For each treat-BMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
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ment, cell viability was evaluated as a percentage using the
following equation: (A570 of treated sample/A570 of untreated
sample) × 100.
Breast cancer cell sensitivity to EVOO phenolics and/or
trastuzumab was expressed in terms of the concentration
of drug required to decrease by 30%, 50% and 70% cell
viability (IC30, IC50 and IC70, respectively). Since the per-
centage of control absorbance was considered to be the
surviving fraction of cells, the IC30, IC50 and IC70values
were defined as the concentration of EVOO phenolics
and/or trastuzumab that produced 30%, 50% and 70%
reduction in control absorbance (by interpolation),
respectively. The degree of sensitization to trastuzumab by
EVOO phenolics was evaluated by dividing IC30 values of
control cells by those obtained when cells were simultane-
ously exposed to EVOO phenols.
Apoptosis assays
The ability of EVOO phenolic compounds to induce
apoptosis was assessed using the Cell Death Detection
ELISAPLUS kit obtained from Roche Diagnostics (Barce-
lona, Spain). Briefly, cells (5 to 10 × 103/well) were grown
in 96-well plates and treated, in duplicates, for 72 h with
the indicated doses of hydroxytyrosol, oleuropein agly-
cone and oleuropein glycoside, as specified. After treat-
ment, the 96-well plates were centrifuged (200 × g) for 10
min. The supernatant was discharged, lysis buffer was
added, and samples were incubated at room temperature
(RT) for 30 min following the manufacturer's instruc-
tions. Anti-histone biotin and anti-DNA peroxidase anti-
bodies were added to each well and incubated at RT for 2
h. After three washes, the peroxidase substrate was added
to each well, and the plates were read at 405 nm at multi-
ple time intervals. The enrichment of histone-DNA frag-
ments in treated cells was expressed as fold increase in
absorbance as compared with control (vehicle-treated)
cells.
Conditioned medium
To prepare conditioned media, cells were plated in 100-
mm tissue culture dishes and cultured in DMEM with
10% FBS until they reached 75–80% confluence. The cells
were washed twice with serum-free DMEM, and incubated
overnight in serum-free DMEM. Cells were then cultured
for 24 h in low-serum (0.1% FBS) DMEM in the presence
or absence of experimental agents, as specified. The super-
natants were collected, centrifuged at 1000 x g, aliquoted,
and stored at -80°C until testing.
HER2- and EGFR-specific Enzyme-Linked Immunosorbent 
Assays
Determination of HER2 and EGFR protein content was
performed with commercially available quantitative ELI-
SAs (Oncogene Science, Bayer Diagnostics) according to
the manufacturer's protocol. To assess the effects of trastu-
zumab and/or EVOO phenolics on HER2 and EGFR pro-
tein concentrations, breast cancer cells, after a 24 h
starvation period in media without serum, were incubated
with trastuzumab, oleuropein aglycone or combinations
of these compounds as specified. After treatment, cells
were washed twice with cold-PBS and then lysed in buffer
(20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate,
1 mM β-glycerolphosphate, 1 mM Na3VO4, 1 μg/ml leu-
peptin, 1 mM phenylmethylsulfonylfluoride) for 30 min-
utes on ice. The lysates were cleared by centrifugation in
an Eppendorff tube (15 minutes at 14,000 × g, 4°C). Pro-
tein content was determined against a standardized con-
trol using the Pierce Protein Assay Kit.
1:50, 1:500; 1: 5,000 and 1:10,000 dilutions of total cell
lysates and conditioned medium from trastuzumab-,
oleuropein aglycone- and trastuzumab + oleuropein agly-
cone-treated and control untreated SKBR3 and SKBR3/
Tzb100 breast cancer cells were used to quantitate HER2
and EGFR protein expression in cell cultures. A standard
curve was generated by using standard solutions as per
manufacturer's instructions. The concentrations of HER2
and EGFR in test samples (in nanograms of HER2 and
EGFR per milligram of total protein) were determined by
interpolation of the sample absorbances from the stand-
ard curve. Each experiment was performed in duplicate
wells.
Activation status of HER2
Testing for phosphor-tyrosine-phosphorylation (activa-
tion) of HER2 was performed by immunoblotting proce-
dures. Briefly, oleuropein aglycone-treated and untreated
control cells were washed twice with cold PBS and then
lysed as described above. Equal amounts of protein (i.e.,
50 μg) were resuspended in 5× Laemli sample buffer for
10 min at 70°C, subjected to electrophoresis on 3–8%
NuPAGE Tris-Acetate and transferred to nitrocellulose
membranes. Non-specific binding on the nitrocellulose
filter paper was minimized by blocking for 1 h at RT with
TBS-T buffer [25 mM Tris-HCl (pH 7.5), 150 mM NaCl,
0.05% Tween 20] containing 5% (w/v) nonfat dry milk.
The treated filters were washed in TBS-T and then incu-
bated with a monoclonal c-erbB2/HER2 (phosphor-spe-
cific) antibody (Ab-18, clone PN2A; NeoMarkers,
Fremont, CA, USA) for 2 h at RT in TBS-T buffer contain-
ing 1% (w/v) nonfat dry milk. The membranes were
washed in TBS-T, horseradish peroxidase-conjugated sec-
ondary antibodies (Jackson Immunoresearch Labs) in
TBS-T were added for 1 h, and immunoreactive bands
were detected by chemiluminescence reagent (Pierce).BMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
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Determination of synergism and antagonism: Isobologram 
analysis
The nature of the interaction between trastuzumab and
oleuropein aglycone was evaluated by the isobologram
technique, a dose-oriented geometric method of assessing
drug interactions [35]. In the isobologram method the
concentration of one agent producing a desired (e.g., 30%
inhibitory) effect is plotted on the horizontal axis, and the
concentration of another agent producing the same
degree of effect is plotted on the vertical axis; a straight
line joining these 2 points represents zero interaction
(additivity) between two agents. The experimental isoef-
fect points are the concentrations (expressed relative to
the IC30 value) of the two agents which when combined
decreased cell viability by 30%. When the experimental
isoeffect points fall below that line, the combination
effect of the two drugs is considered to be supra-additive
or synergistic, whereas antagonism occurs if the point lies
above it. A quantitative index of these interactions was
provided by the isobologram equation CI30 = (a/A) + (b/
B), where, for this study, A and B represent the respective
concentrations of trastuzumab and oleuropein aglycone
required to produce a fixed level of inhibition (IC30) when
administered alone, a and b represent the concentrations
required for the same effect when trastuzumab and oleu-
ropein aglycone were administered in simultaneous com-
bination, and CI30 represents an index of drug interaction
(Combination Index). CI values of < 1 indicate synergy, a
value of 1 represents additivity, and values of > 1 indicate
antagonism. For all estimations of CI30, we used only iso-
boles where intercept data for both axes were available.
Statistics
Two-group comparisons were performed by the Student t
test for paired and unpaired values. Comparisons of
means of ≥ 3 groups were performed by ANOVA, and the
existence of individual differences, in case of significant F
values at ANOVA, tested by Scheffé's multiple contrasts.
Results
Effects of EVOO phenolic compounds on breast cancer cell 
viability: Oleuropein aglycone preferentially kills HER2 
oncogene-overexpressing breast cancer cells
The anti-tumor effects of four representative EVOO phe-
nolics were initially assessed by characterizing the meta-
bolic status of MCF-7, MCF-7/HER2 and SK-Br3 breast
cancer cell lines treated with micromolar concentrations
(6.25 → 100 μM) of tyrosol, hydroxytyrosol, oleuropein
aglycone, and oleuropein glycoside. MCF-7 breast cancer
cells naturally express physiological levels of HER2. We
stably transduced MCF-7 cells with pBABE-HER2 or
pBABE (control) retroviral vectors and confirmed HER2
expression by immunoblotting (data not shown). When
quantitative measurements of the concentration of HER2
cells were performed using the Human neu Quantitative
Enzyme-Linked Immunosorbent Assay (ELISA) System
(Oncogene Science, Cambridge, MA, USA) and results
were expressed as nanograms of HER2 per mg of total pro-
tein, cell lysates from empty vector-transduced MCF-7/
pBABE cells and MCF-7/HER2 cells were found to stably
express ~100 ng HER2 mg protein-1 and ~7000 ng HER2
mg protein-1, respectively. This level of HER2 overexpres-
sion achieved in MCF-7/(pBABE)HER2 cells (~70-fold
increase when compared to MCF-7/pBABE matched con-
trol and MCF-7 parental cells) was comparable to that
reported in MCF-7/Her2-18 cells, a well-characterized
MCF-7-derived HER2-overexpressing clone engineered to
stably express the full-length human HER2 cDNA control-
led by a SV40 viral promoter [36]. SKBR3 cells represent a
widely used tumor cell in vitro model characterized by
exhibiting natural HER2 gene amplification, HER2 recep-
tor protein overexpression (~1000 ng HER2 mg protein-1)
and HER2-dependency for cell proliferation and survival
[37]. After 5 days of treatment, cell numbers were meas-
ured using a tetrazolium salt-based (MTT) assay (Figure
1).
Treatment with tyrosol failed to reduce cell viability in the
entire panel of cell lines evaluated in our study (Figure
1A). Hydroxytyrosol exposure slightly but significantly
reduced cell viability at the highest concentrations tested
(i.e., 50 and 100 μM) when used in the SKBR3 breast can-
cer cell line (Figure 1B). A completely different picture
emerged when we evaluated the growth inhibitory effects
of oleuropein aglycone: First, all the cell lines were
growth-inhibited in a dose-dependent fashion upon the
addition of oleuropein aglycone (Figure 1C). Second, we
observed a positive correlation between the expression
levels of HER2 oncogene and the efficacy of oleuropein
aglycone (Table 1). Oleuropein aglycone's IC30 (the con-
centration of the compound necessary to reduce cell via-
bility by 30% -cytostasis-) was as low as 28 μM (95% CI =
25–31 μM) in SKBR3 cells -which bear HER2 gene ampli-
fication- whereas this value was greater than 100 μM in
MCF-7 cells -which express physiological levels of HER2
(i.e., one single copy of HER2 gene)-. Moreover, forced
overexpression of HER2 in MCF-7 cells resulted in a
"SKBR3-assimilated" oleuropein aglycone-sensitive phe-
notype. Thus, oleuropein aglycone's IC30 value in MCF-7/
(pBABE)HER2 cells dropped to 35 μM (95% CI = 30–40
μM). This HER2-related sensitivity to oleuropein aglycone
was also obvious when analyzing IC50 and IC70 cytotoxic
values in MCF-7, MCF-7/(pBABE)HER2 and SKBR3 cells
(Table 1). In order to investigate whether the glucose moi-
ety in oleuropein structure affected its anti-tumoral activ-
ity, we finally evaluated the growth inhibitory effects of its
precursor form (i.e., oleuropein glycoside; Figure 1D).
Interestingly, oleuropein glycoside was ineffective at
inducing any significant cytostatic or cytotoxic effect
regardless of the HER2 status of breast cancer cells (FigureBMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
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1D, Table 1). These findings reveal that, among EVOO
polyphenols tested, oleuropein aglycone was the most
potent EVOO phenolic in decreasing breast cancer cell
viability. Also of interest, it is evident that HER2 onco-
gene-overexpressing breast cancer cells exhibit an exacer-
bated sensitivity to oleuropein aglycone-induced
cytotoxicity.
Oleuropein aglycone preferentially induces apoptotic cell 
death in HER2-overexpressing breast cancer cells
We speculated that the increased sensitivity to oleuropein
aglycone that occurs in HER2-overexpressing breast can-
cer cells was not simply the result of changes in cell prolif-
eration, but it might actually be due to changes in
apoptotic cell death. To address this question, cells were
exposed to increasing concentrations of oleuropein agly-
cone, apoptotic cell death was measured by a Cell Death
ELISA that detects apoptosis-induced DNA-histone frag-
mentation, and the x-fold increase in apoptosis was calcu-
lated by comparing the ELISA optical density readings of
treated samples, with the values of untreated cells as 1.0.
HER2-negative MCF-7 cells exhibited the lowest degree of
apoptosis upon treatment with oleuropein aglycone (up
to 1.8-fold increase versus 1.0-fold in untreated control
MCF-7 cells; Figure 2, left panel). Interestingly, forced
expression of HER2 in MCF-7 cells increased by ~2-fold
the apoptotic effects of oleuropein aglycone. Thus, treat-
ment with 50 μM oleuropein aglycone increased apop-
Effects of EVOO phenolics on breast cancer cell viability Figure 1
Effects of EVOO phenolics on breast cancer cell viability. MCF-7, MCF-7/(pBABE)HER2 and SKBR3 cells were incu-
bated with various concentrations of tyrosol (A), hydroxytyrosol (B), oleuropein aglycone (C) and oleuropein glycoside (D) for 
5 days. Cell growth, measured using MTT assay, was expressed as % of untreated cells (blue line = 100% cell viability). Results 
are means (columns) and 95% confidence intervals (bars) of three independent experiments made in triplicate. Statistically signif-
icant differences (one-factor ANOVA analysis) between experimental conditions and unsupplemented control cells are shown 
by asterisks (* P < .01, ** P < .001). All statistical tests were two-sided.BMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
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totic cell death by 3.2 times in MCF-7/(pBABE)HER2 cells
(Figure 2, middle panel). HER2-overexpressing SKBR3 cells
were exquisitely sensitive to oleuropein aglycone-induced
apoptosis. They exhibited the highest degree of apoptotic
cell death following exposure to oleuropein aglycone (up
to ~6.0-fold increase versus 1.0-fold in untreated control
SKBR3 cells; Figure 2, right panel). The results support the
notion that HER2 overexpression associates with an
increased sensitivity to oleuropein aglycone-induced
breast cancer cell damage (Figure 3).
Co-exposure to oleuropein aglycone synergistically 
enhances trastuzumab-efficacy in HER2-overexpressing 
and trastuzumab-sensitive SKBR3 breast cancer cells
We explored whether an exacerbated response of HER2-
overexpressing breast cancer cells to oleuropein aglycone
could be exploited to positively modulate the growth
inhibitory effects of trastuzumab (Herceptin™), a human-
ized monoclonal antibody binding with high affinity to
the ectodomain of p185HER2 oncoprotein [38-40]. The
sensitizing effects of oleuropein aglycone on the sensitiv-
ity of HER2-overexpressing and trastuzumab-sensitive
SKBR3 cells to trastuzumab are shown in Table 2. In order
to measure changes in trastuzumab efficacy in the absence
or presence of oleuropein aglycone, a "sensitization fac-
tor" was determined by dividing the IC30 value for trastu-
zumab as single agent by those IC30 values obtained upon
co-exposure to graded concentrations of oleuropein agly-
cone. Oleuropein aglycone enhanced the growth inhibi-
tory effects of trastuzumab in a dose-dependent manner.
Thus, as the concentration of oleuropein aglycone, the
efficacy of trastuzumab was significantly augmented.
Remarkably, a 50-fold increase in the anti-proliferative
effects of trastuzumab was observed in the presence of 25
μg/ml oleuropein aglycone (Table 2).
Oleuropein aglycone significantly decreased cell viability
of SKBR3 breast cancer cells at some of the concentrations
examined. This indicated the presence of a potentially sig-
nificant additive/antagonist component. Thus, possible
synergistic interactions between oleuropein aglycone and
trastuzumab could not be accurately discriminated from
additive or antagonistic effects in the basis of the above
data alone. Although there is still controversy over which
method is the best for detecting true in vitro synergy
between drug combinations, we performed a series of iso-
bologram transformations of multiple dose-response
analyses [35]. A representative transformation is pre-
sented graphically (isobologram) in Figure 4. The straight
line drawn between the IC30  for oleuropein aglycone
alone and the IC30 for trastuzumab alone indicates the
alignment of theoretical isoeffect data points for additive
interactions. The true IC30 values (the experimental con-
centrations of oleuropein aglycone and trastuzumab
which combined produced 30% reduction in cell viabil-
ity) were plotted and compared with the additive line.
Data points above the dashed line of the additive effects
in the isobole suggest antagonism, and those below the
diagonal suggest synergism. In our experiments, all the
experimental isoeffect data points fell in the left side of the
additive line, clearly denoting a synergistic effect when
combining oleuropein aglycone and trastuzumab in
SKBR3 breast cancer cells. While this figure provided a
graphical representation of the nature of the interaction
between oleuropein aglycone and trastuzumab, the value
of the mean Combination Index30 (CI30) further revealed
that the amount of the two agents necessary to reduce cell
viability by 30% in SKBR3 cells was only 0.671 times as
much as it would be required if they demonstrated purely
additive actions. The nature of the interaction obtained by
using the isobologramic methodology strongly suggests
Table 1: Effects of EVOO phenolics on breast cancer cell viability
TYROSOL HYDROXYTYROSOL OLEUROPEIN AGLYCONE OLEUROPEIN GLYCOSIDE
IC30 IC50 IC70 IC30 IC50 IC70 IC30 IC50 IC70 IC30 IC50 IC70
MCF-7 N.A. N.A. N.A. N.A. N.A. N.A. ~105 N.A. N.A. N.A. N.A. N.A.
MCF-7/HER2 N.A. N.A. N.A. N.A. N.A. N.A. 35
(95% CI = 
30–40)
85
(95% CI = 
82–88)
N.A. N.A. N.A. N.A.
SK-Br3 ~120 N.A. N.A. ~110 N.A. N.A. 28
(95% CI = 
25–31)
47
(95% CI = 
43–51)
82
(95% CI = 
80–84)
~110 N.A. N.A.
The metabolic status of tyrosol-, hydroxytyrosol-, oleuropein aglycone-, and oleuropein glycoside-treated MCF-7, MCF-7/(pBABE)HER2 and SKBR3 
breast cancer cells was evaluated using a MTT-based cell viability assay and constructing dose-response curves as described in "Methods". Inhibitory 
Concentrations (IC) producing the IC30, IC50 and IC70 values (the concentration of each agent needed to reduce cell viability by 30%, 50% and 70% 
relative to untreated control cells, respectively) were calculated by interpolation. Values are means (in μM) and 95% confidence intervals (95% CI) 
of three independent experiments made in triplicate.
N.A. Not Available.BMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
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that concurrent supplementation with oleuropein agly-
cone synergistically works to enhance the growth inhibi-
tory activity of the anti-HER2 monoclonal antibody
trastuzumab.
Oleuropein aglycone reduces the proteolytic cleavage of 
the HER2 extracellular domain (ECD)
To obtain some preliminary insights on the mecha-
nism(s) by which oleuropein aglycone affected the effi-
cacy of trastuzumab, we investigated the effects of
oleuropein aglycone on the activation status of HER2
oncoprotein. The activation status of HER2, and not just
its overexpression, is a crucial event determining both the
aggressive biological behavior of HER2 positive-breast
carcinomas and the responses of HER2 positive-breast
tumors to chemotherapy, anti-estrogens and, more
importantly for this study, to the anti-HER2 antibody tras-
tuzumab [41-45]. Although the mechanism of activation
of the HER2 oncoprotein is not completely understood, in
vitro and in vivo HER2 activation has been demonstrated
to occur as a consequence of proteolytic cleavage of its
extracellular domain (ECD), a key event for downstream
signaling [46]. Indeed, the inhibition of basal and acti-
vated cleavage of the HER2 ECD represents a key mecha-
Effects of oleuropein aglycone on breast cancer apoptotic cell death Figure 2
Effects of oleuropein aglycone on breast cancer apoptotic cell death. Quantification of apoptosis-related cell death in 
MCF-7, MCF-7/(pBABE)HER2 and SKBR3 cells treated with increasing concentrations of oleuropein aglycone was determined 
by Cell Death ELISA as described in "Material and methods". The enrichment of histone-DNA fragments in oleuropein agly-
cone-treated cells was expressed as fold-increase in absorbance by comparing with control (vehicle-treated) cells using the fol-
lowing formula: [A405 – A490]TREATED/[A405-A490]UNTREATED. Data are the mean (columns) and 95% confidence intervals (bars) of 
three independent experiments performed in duplicate. One-factor ANOVA was used to analyze differences in the percentage 
of apoptosis between the various treatment groups and the control group. * P < .01; ** P < .001; N.S.: Not statistically signifi-
cant (one-factor analysis of variance). All statistical tests were two-sided.BMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
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nism of action of trastuzumab as it prevents the
production of an active (phosphorylated) form of HER2
in breast cancer cells [47]. Serum-starved SKBR3 cells were
incubated for 24 h in the absence or presence of various
concentrations of oleuropein aglycone (0, 50 and 100
μM). ELISA-based quantitative measurements of the con-
centration of HER2 ECD in the conditioned media from
oleuropein aglycone-treated and untreated-control SKBR3
cells revealed that HER2 ECD significantly decreased by
47% in the presence of 50 μM oleuropein aglycone, while
HER2 ECD dramatically decreased by 71% when SKBR3
cells were treated with 100 μM oleuropein aglycone (Fig-
ure 5A). To further confirm that oleuropein aglycone-
induced down-regulation of HER2 ECD was indeed asso-
ciated with changes in the HER2 tyrosine kinase signaling,
we evaluated the phosphorylation status of the 1248 tyro-
sine residue (Tyr1248), which constitutes the main auto-
phosphorylation site of HER2. When immunoblotting
analyses were performed using a monoclonal c-erbB2/
HER2 (phosphor-specific) Ab-18 (clone PN2A), which
specifically recognizes the activated, tyrosine phosphor-
ylated (P-Tyr1248) form of HER2 [48,49], we observed
decreased tyrosine kinase activities (smaller PN2A bands)
in oleuropein aglycone-treated SKBR3 cells (Figure 5A).
These findings demonstrate that exogenous supplementa-
tion with oleuropein aglycone significantly down-regu-
lates the concentration of HER2 ECD and, consequently,
the activation status of HER2 oncoprotein.
Oleuropein aglycone suppresses HER2 overexpression and 
synergistically enhances trastuzumab-induced down-
regulation of HER2 oncoprotein
Considering that trastuzumab-induced inhibition of
HER2 ECD cleavage precedes trastuzumab-induced
down-regulation of cell surface-associated HER2 [46,47],
we speculated that concurrent supplementation with
oleuropein aglycone may sensitize breast cancer cells to
the well-known down-regulatory actions of trastuzumab
on HER2 [50,51]. To test this hypothesis, total HER2 lev-
els were quantitatively measured by ELISA after a 72 h
treatment with graded concentrations of oleuropein agly-
cone (0, 50 and 100 μM; Figure 5B). Total HER2 expres-
sion in cell lysates from HER2-overexpressing SKBR3 cells
was reduced by 64% in the presence of 100 μM oleuro-
pein aglycone. Moreover, the simultaneous combination
of sub-optimal concentrations of trastuzumab and oleu-
ropein aglycone reduced HER2 more than when either
agent was administered alone. Thus, 10 μg/ml trastuzu-
mab and 50 μM oleuropein aglycone induced an 84%
decrease in the expression levels of HER2 when concur-
rently combined in SKBR3 cells, whereas when used
alone, trastuzumab and oleuropein aglycone caused a
24% and 26% HER2 down-regulation, respectively (Fig-
ure 5C). These findings clearly demonstrate that the
EVOO polyphenol oleuropein aglycone depletes HER2
receptor from cell-surface in breast cancer cells naturally
exhibiting HER2 gene amplification and HER2 protein
overexpression (i.e., SKBR3 cells). Moreover, a synergistic
augmentation of trastuzumab-induced down-regulation
of HER2 expression occurs in oleuropein aglycone-sup-
plemented SKBR3 breast cancer cells.
Positive correlation between HER2 overexpression and  breast cancer cell sensitivity to oleuropein aglycone Figure 3
Positive correlation between HER2 overexpression and 
breast cancer cell sensitivity to oleuropein aglycone.
Table 2: Effects of oleuropein aglycone on the sensitivity of SKBR3 cells to trastuzumab a
Oleuropein aglycone (μM) TRASTUZUMAB IC30 (μg/ml) Sensitization factor (x-fold)b
01 8-
3.125 10 2
6.25 4.5 4
12.5 1.1 16
25 0.36 50
a Data represent the cell viability effects upon simultaneous exposure of HER2-positive and trastuzumab-sensitive SKBR3 breast cancer cells to 
oleuropein aglycone and trastuzumab. Briefly, SKBR3 cells were incubated in serial dilutions of trastuzumab in the absence or presence of a given 
concentration of oleuropein aglycone. IC30 values are the concentrations of trastuzumab which decreased cell viability by 30%, measured by using a 
MTT assay as described in "Methods". Values are mean of three independent experiments carried out in triplicate.
b Sensitization factors were obtained by dividing the IC30 value of trastuzumab as single agent by the IC30 values obtained when oleuropein aglycone 
was concomitantly supplemented.BMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
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Oleuropein aglycone reverses acquired autoresistance to 
trastuzumab
Not all the HER2-overexpressing breast carcinomas
respond to treatment with trastuzumab, and its clinical
benefit is limited by the fact that resistance develops rap-
idly in virtually all trastuzumab-treated patients. Indeed,
the majority of patients who achieve an initial response to
trastuzumab develop resistance within 1 year [52-54].
This dilemma is becoming increasingly important as
recent studies strongly support a role for trastuzumab in
the adjuvant setting for HER2-overexpressing early-stages
breast cancers [55-57]. Although it is likely that combin-
ing trastuzumab with other therapeutics for targeting
HER2 should increase the magnitude and duration of
response to trastuzumab [53,54], there are few data con-
cerning novel strategies able to sensitize HER2-overex-
pressing breast cancer cells to the growth-inhibitory
effects of trastuzumab [58]. Considering that oleuropein
aglycone-promoted cell growth inhibition and apoptosis
was significantly higher in HER2-overexpressing than in
HER2-negative breast cancer cells, which was concomi-
tant with a significant depletion of the HER2 oncoprotein,
we hypothesized that oleuropein aglycone may represent
a novel biological anti-HER2 agent capable to reverse
auto-acquired resistance to trastuzumab-based treat-
ments.
In order to generate a preclinical model of acquired resist-
ance to trastuzumab, HER2-overexpressing SKBR3 cells
were exposed for approximately 3 months to 20 μg/ml
trastuzumab. At this point and as previously reported by
Nahta  et al., cells regained morphology similar to the
parental line [59]. SKBR3/Tzb20 cells were then continu-
ously grown in culture medium supplemented with 185
μg/ml trastuzumab over a period time of at least two
months. These doses were chosen because clinical trials in
humans have shown plasma concentrations ranging from
~20 μg/ml to 185 μg/ml trastuzumab [58]. Cells are now
maintained in 100 μg/ml trastuzumab, a concentration at
which parental cells are strongly impaired in their meta-
bolic status (Figure 6A). Indeed, the IC30 (30% growth
inhibitory) value for trastuzumab was found to signifi-
cantly increase from 18 ± 3 μg/ml in trastuzumab-sensi-
tive SKBR3 parental cells to 110 ± 5 μg/ml in trastuzumab-
conditioned (high-dose resistant) SKBR3/Tzb100 cells.
Interestingly, this ~6-fold decrease in the efficacy of trastu-
zumab was entirely reversed when SKBR3/Tzb100 cells
were co-cultured in the presence of oleuropein aglycone
(Table 3). When sensitization factors were calculated by
dividing the IC30 values of trastuzumab in the absence of
oleuropein aglycone by those in the presence of oleuro-
pein aglycone, oleuropein aglycone was found to dramat-
ically enhance the activity of trastuzumab > 1,000 times.
The precise nature of the interaction between trastuzumab
and oleuropein aglycone was investigated further using
the isobologram analysis (Figure 6B). When the experi-
mental isoeffect points (the concentrations of trastuzu-
mab and oleuropein aglycone that, when combined,
produced a 30% reduction in the survival of SKBR3/
Tzb100 cells) were plotted and compared with the addi-
tive line, the data points fell in the left of the line and close
to the X-Y axes, thus suggesting a strong supra-additive or
synergistic interaction between the two agents (Figure
6B). Indeed, the combined quantity of trastuzumab and
oleuropein aglycone necessary to reduce SKBR3/Tzb100
Synergy analyses of the interaction between oleuropein agly- cone and Tzb against in Tzb-sensitive SKBR3 cells Figure 4
Synergy analyses of the interaction between oleuro-
pein aglycone and Tzb against in Tzb-sensitive 
SKBR3 cells. The nature of the interaction between oleuro-
pein aglycone and trastuzumab was evaluated by the isobolo-
gram technique, a dose-oriented geometric method of 
assessing drug interactions. Upon this approach, the concen-
tration of oleuropein aglycone producing a desired (e.g., 30% 
inhibitory) effect was plotted on the horizontal axis, and the 
concentration of trastuzumab producing the same cytostatic 
degree was plotted on the vertical axis; a straight line joining 
these two points represents zero interaction between the 
two agents (CI30 = 1.0, additivity). An experimental isoeffect 
point is the concentration (expressed relative to oleuropein 
aglycone and trastuzumab IC30 concentrations) of the two 
agents which when combined reduced cell viability by 30%. 
Within the designed assay range, a set of isoeffect points was 
generated because there were multiple oleuropein aglycone 
and trastuzumab concentrations that achieved the same iso-
effect. In our present study, the mean values of the survival 
fractions were used to generate the set of experimental iso-
effect points and construct the isobole for the oleuropein 
aglycone-trastuzumab combination. Data points above the 
diagonal line of the additive effects in the isobole suggest 
antagonism and those below the diagonal suggest synergism. 
The value of the mean CI30 value is also labeled. Student t 
tests were applied to formally evaluate whether synergism or 
antagonism was evident as compared to a null-hypothesized 
CI30 of 1,0; * P < .01, ** P < .001).BMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
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cell viability by 30% was only ~0.2 times the quantity
required if they demonstrated purely additive behavior (P
< .001 compared with a null-hypothesized combination
index of 1.0,i.e., additive). These findings are pioneering
describing how a phytochemical naturally found in
EVOO (i.e., oleuropein aglycone) can entirely restore tras-
tuzumab efficacy in breast cancer cells with acquired
resistance to trastuzumab.
Oleuropein aglycone inhibits HER2 "super-expression" in 
trastuzumab-resistant breast cancer cells
The drawbacks to our approach (i.e., trastuzumab-resist-
ant pool from once cell line) are that pools may contain
cells with various degrees of resistance and that the pool
developed during this study may harbor resistance
acquired over time or may represent a selected subpopu-
lation of cells with inherent resistance. However, pools
Exogenous supplementation with oleuropein aglycone inhibits HER2 ECD cleavage and HER2 autophosphorylation (activation),  down-regulates HER2 expression and synergistically enhances trastuzumab-induced depletion of HER2 in trastuzumab-sensi- tive SKBR3 cells Figure 5
Exogenous supplementation with oleuropein aglycone inhibits HER2 ECD cleavage and HER2 autophosphor-
ylation (activation), down-regulates HER2 expression and synergistically enhances trastuzumab-induced 
depletion of HER2 in trastuzumab-sensitive SKBR3 cells. A. Overnight serum-starved SKBR3 cells were cultured in 
DMEM-0.1% FBS in the absence or presence of increasing concentrations of oleuropein aglycone for 24 h. Top. The Oncogene 
Science HER2 microtiter ELISA was used according to the manufacturer's instructions to compare HER2 ECD concentrations 
in conditioned media from oleuropein aglycone-treated and untreated control cells. Results are means (columns) and 95% con-
fidence intervals (bars) of three independent experiments made in triplicate. Statistically significant differences (one-factor 
ANOVA analysis) between experimental conditions and unsupplemented control cells are shown by asterisks (* P < .01, ** P < 
.001). All statistical tests were two-sided. Bottom. The activation status of HER2 oncoprotein upon treatment with increasing 
concentrations of oleuropein aglycone was tested using a Phosphor-Tyr1248-HER2 immunoblotting procedure as described in 
"Material and methods". Figure shows a representative immunoblotting analysis. Equivalent results were obtained in, at least, 
three independent experiments. B, C. Overnight serum-starved SKBR3 cells were cultured in DMEM-0.1% FBS supplemented 
with increasing concentrations of oleuropein aglycone in the absence or presence of trastuzumab for 72 h. The Oncogene Sci-
ence HER2 microtiter ELISA was used according to the manufacturer's instructions to compare HER2 concentrations in cell 
pellets. Results are means (columns) and 95% confidence intervals (bars) of three independent experiments made in triplicate. 
Statistically significant differences (one-factor ANOVA analysis) between experimental conditions and unsupplemented control 
cells are shown by asterisks (* P < .01, ** P < .001). All statistical tests were two-sided.BMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
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also represent the alterations that are represented in the
majority of tumor cell populations, whereas clones -
another approach that would have been used to answer
our research question- represent just one isolated altera-
tion. Nonetheless, to eliminate the possibility of HER2-
independent mechanisms for the sensitizing effects of
oleuropein aglycone on trastuzumab-resistant breast can-
cer cells, we performed HER2-specific ELISAs to quantita-
tively determine the expression levels of HER2 in SKBR3/
Tzb100 cells. This resistant pool, when maintained in the
absence of trastuzumab for 72 h, exhibited HER2 levels
notably higher to those found in trastuzumab-sensitive
SKBR3 parental cells (~2-fold increase; Figure 7). This
"HER2 super-expression", which has not been reported in
earlier trastuzumab-resistant breast cancer models [58-
60], decreased back and even below the baseline HER2
level found in trastuzumab-sensitive SKBR3 parental cells
when SKBR3/Tzb100 cells were treated with oleuropein
aglycone (up to 71% reduction; Figure 7A). Trastuzumab
exposure was still capable to reduce HER2 by 21% in
SKBR3/Tzb100 cells (a percentage comparable to that
found in trastuzumab-sensitive SKBR3 parental cells).
Interestingly, trastuzumab treatment drastically down-
regulated HER2 expression by 83% in the presence of 50
μM oleuropein aglycone, which, as single agent, decreased
HER2 "super-expression" by 43% in SKBR3/Tzb100 cells.
Oleuropein aglycone shows specificity for HER2 among 
other HER members
The HER2 receptor is a member of a highly homologue
family of receptor tyrosine kinases (RTK) comprising c-
erbB1 (EGFR, HER1), c-erbB2 (HER2), c-erbB3 (HER3)
and c-erbB4 (HER4) [61-64]. Moreover, the EGFR/HER2
ratio is known to play a key role in the efficiency of the
A. Scheme for development of a new model of breast cancer autoresistance to trastuzumab Figure 6
A. Scheme for development of a new model of breast cancer autoresistance to trastuzumab. In order to gener-
ate a preclinical model of acquired resistance to trastuzumab, HER2 gene-amplified SKBR3 cells were exposed for approxi-
mately 3 months to 20 μg/ml trastuzumab (Phase I, top panel). At this point, SKBR3/Tzb20 cells regained morphology similar to 
the parental (trastuzumab-sensitive) SKBR3 cell line. SKBR3/Tzb20 cells were then continuously grown in culture medium sup-
plemented with 185 μg/ml trastuzumab over a period time of at least one month (Phase II, bottom panel). At this point, SKBR3/
Tzb100 cells gained new cell morphology. Cells were then maintained in 100 μg/ml trastuzumab, a concentration of trastuzu-
mab at which SKBR3 parental cells are strongly impaired in their metabolic status. More than 8 months later, SKBR3/Tzb100 
cells normally proliferate in the presence of 100 μg/ml trastuzumab. B. Synergy analyses of the interaction between 
oleuropein aglycone and Tzb against in Tzb-conditioned (high-dose resistant) SKBR3/Tzb100 cells. The nature 
of the interaction between oleuropein aglycone and trastuzumab was evaluated by the isobologram technique as described in 
Figure 3.BMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
Page 13 of 19
(page number not for citation purposes)
oncogenic signaling driven by HER2 overexpression [61-
65]. Therefore, it could be argued that oleuropein agly-
cone-induced inhibition of HER2 expression may rather
reflects a wider and unspecific inhibitory effect against
other HER members. To test this hypothesis, we quantita-
tively assessed the expression levels of EGFR (HER1) fol-
lowing exposure to trastuzumab in the absence or
presence of oleuropein aglycone. Neither trastuzumab
nor oleuropein aglycone treatments alone or in concur-
rent combination caused detectable changes in EGFR
expression in SKBR3 parental cells (Figure 7B).
Trastuzumab inhibits cell proliferation by driving cells
into quiescence more effectively when EGFR content is
low, while a high EGFR content renders breast cancer cells
less susceptible to trastuzumab [65]. Therefore, we finally
evaluated whether oleuropein aglycone altered EGFR lev-
els in trastuzumab-conditioned SKBR3/Tzb100 cells. It is
noteworthy that the acquisition of trastuzumab resistance
was accompanied by up-regulatory changes in the expres-
sion levels of EGFR (~3-times when compared to those
found in trastuzumab-sensitive SKBR3 parental cells).
Oleuropein aglycone failed to alter EGFR expression levels
in SKBR3/Tzb100 cells (Figure 7B). These data strongly
suggest that, among members of the oncogenic HER net-
work, the inhibitory effects of the EVOO polyphenol oleu-
ropein aglycone are significantly and specifically restricted
to HER2.
Discussion
The term "Mediterranean diet" refers to dietary patterns
found in olive-growing areas of the Mediterranean region
and described in the 1960s and beyond. Epidemiological
studies have shown that populations consuming a pre-
dominantly olive oil-based Mediterranean-style diet
exhibit lower incidences of breast cancer and other
chronic diseases than those eating a northern European or
North American diet. Most of the attention has been so far
paid to the fat components-related anti-cancer effects of
the "Mediterranean diet". In this regard, we recently estab-
lished the anti-oncogenic actions of the olive oil ω-9
MUFA OA in cultured cancer cells [9,11,19-21]. However,
it should be noted that OA is one of the predominant FAs
in largely-consumed animal foods and it is therefore
unlikely that OA content is the unique responsible agent
for the healthful properties of olive oil [17]. In fact, it is
reasonable to hypothesize that some of the phenolic com-
pounds present in olive oil -which have been shown to
afford considerable protection against aging, coronary
heart disease and cancer by inhibiting, for instance, oxida-
tive stress [2,5,11-18]– may also exhibit "OA-like" anti-
breast cancer effects. In agreement with this hypothesis,
our current findings reveal that among EVOO phenolics
tested, oleuropein aglycone is a potent phytochemical
that significantly decreases breast cancer cell proliferation
and survival by sharing OA's ability to suppress both the
expression and the activity of HER2 oncogene in cultured
breast cancer cells.
A significantly higher cytotoxic activity of the aglyconic,
compared with the glycosidic, form of oleuropein was
clearly observed in all the breast cancer cell lines
employed in our study. This difference possibly derives
from the greater lipophilicity of the former, a property
that should allow better cell membrane incorporation
and/or interaction with other lipids [66,67]. Since an
important step in the body metabolism of EVOO
polyphenols might be that oleuropein aglycone is split
into hydroxytyrosol or tyrosol and elenolic acid [13,68-
70], it will be relevant to evaluate whether the dihydroxy
moiety of oleuropein (i.e., hydroxytyrosol) and/or the iri-
doid moiety (i.e., elenolic acid) can recapitulate (entirely
or solely in part) oleuropein aglycone-induced breast can-
cer cell growth inhibition and apoptotic breast cancer cell
death. Our findings strongly suggest that: First, upon β-
glucosidase-induced deglucosidation of the iridoid glyco-
side moiety of oleuropein (i.e., activation of the glycoside
form of oleuropein) [71], the aglyconic form of oleuro-
pein can exhibit growth inhibitory and pro-apoptotic
activities against human breast cancer cells. Second,
although the hydroxytyrosol moiety was notably less cyto-
toxic than oleuropein aglycone it was still capable to sig-
Table 3: Effects of oleuropein aglycone on the sensitivity of SKBR3/Tzb100 cells to trastuzumab a
Oleuropein aglycone (μM) TRASTUZUMAB IC30 (μg/ml) Sensitization factor (x-fold)b
0 110 -
3.125 3.7 30
6.25 0.13 846
12.5 0.045 > 1,000
25 0.0075 > 1,000
a Data represent the cell viability effects upon simultaneous exposure of HER2-positive and trastuzumab-conditioned (resistant) SKBR3/Tzb100 
breast cancer cells to oleuropein aglycone and trastuzumab. Briefly, SKBR3 cells were incubated in serial dilutions of trastuzumab in the absence or 
presence of a given concentration of oleuropein aglycone. IC30 values are the concentrations of trastuzumab which decreased cell viability by 30%, 
measured by using a MTT assay as described in "Methods". Values are mean of three independent experiments carried out in triplicate.
b Sensitization factors were obtained by dividing the IC30 value of trastuzumab as single agent by the IC30 values obtained when oleuropein aglycone 
was concomitantly supplemented.BMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
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nificantly promote breast cancer apoptotic cell death.
However, the elenolic acid moiety notably loses the anti-
breast cancer actions of oleuropein aglycone (data not
shown). Although the ultimate reason determining the
pro-apoptotic potencies of EVOO phenolics should be
analyzed in future studies, it is reasonable to argue that
EVOO phenolic compounds with a simple structure (i.e.,
involving only a single phenol ring) cannot exert anti-
breast cancer actions, and that a more complex structure
(i.e., involving two or more phenol rings) may be required
to exert cytotoxic effects in breast cancer cells. In accord-
ance with this idea, Carluccio et al. reported that oleuro-
pein aglycone was much more potent than tyrosol or
hydroxytyrosol in decreasing adhesion molecule expres-
sion on cultured human endothelial cells [72]. Also, the
anti-oxidant properties of oleuropein aglycone's moieties,
which are similarly exhibited by hydroxytyrosol but they
disappear in the case of elenolic acid [16-18,66,67,72],
may account for the dissimilar ability of EVOO phenolics
to inhibit breast cancer cell growth.
Oleuropein has recently been shown to efficiently inhibit
the growth of T47D breast cancer cells, and its growth
inhibitory effect was mediated, at least in part, by acting as
cytoskeleton disruptor [73]. T47D cells express physiolog-
ical levels of the HER2 oncogene. Here, we reveal that
inhibition of HER2 expression/activity is a previously
unrecognized molecular mechanism through which the
EVOO polyphenol oleuropein aglycone can exert its
tumoricidal effects in human breast cancer cells. This anti-
HER2 action, in turn, synergistically works with the anti-
HER2 monoclonal antibody trastuzumab to down-regu-
A. Exogenous supplementation with oleuropein aglycone down-regulates HER2 expression and synergistically enhances trastu- zumab-induced depletion of HER2 in trastuzumab-resistant SKBR3/Tzb100 cells Figure 7
A. Exogenous supplementation with oleuropein aglycone down-regulates HER2 expression and synergistically 
enhances trastuzumab-induced depletion of HER2 in trastuzumab-resistant SKBR3/Tzb100 cells. Overnight 
serum-starved SKBR3/Tzb100 cells were cultured in DMEM-0.1% FBS supplemented with increasing concentrations of oleuro-
pein aglycone in the absence or presence of trastuzumab for 72 h. The Oncogene Science HER2 microtiter ELISA was used 
according to the manufacturer's instructions to compare HER2 concentrations in cell pellets. B. Oleuropein aglycone 
treatment does not affect EGFR (HER1) expression in trastuzumab-sensitive SKBR3 parental cell line (SKBR3/
Wild Type) and in its derivative trastuzumab-resistant SKBR3/Tzb100 pool. Overnight serum-starved SKBR3/
Tzb100 cells were cultured in DMEM-0.1% FBS supplemented with increasing concentrations of oleuropein aglycone in the 
absence or presence of trastuzumab for 72 h. The Oncogene Science HER1 (EGFR) microtiter ELISA was used according to 
the manufacturer's instructions to compare HER1 concentrations in cell pellets. Results in A and B are means (columns) and 
95% confidence intervals (bars) of three independent experiments made in triplicate. Statistically significant differences (one-
factor ANOVA analysis) between experimental conditions and unsupplemented control cells are shown by asterisks (* P < .01, 
** P < .001). All statistical tests were two-sided.BMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
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late HER2 expression. Moreover, upon development of
trastuzumab-resistant breast cancer cells, oleuropein agly-
cone was found to fully overcome trastuzumab resistance
while suppressing the extremely high levels of HER2
occurring in trastuzumab-conditioned (high-dose resist-
ant) SKBR3/Tzb100 cells. Although the ultimate molecu-
lar mechanism underlying oleuropein aglycone-induced
down-regulation of HER2 remains to be elucidated, our
current findings, altogether, strongly suggest that: a.) it
should be, at least in part, different to that of trastuzumab
(i.e., targeting of HER2 ECD and subsequent HER2 recep-
tor degradation) as SKBR3/Tzb100 cells did not exhibit
cross-resistance to the anti-HER2 effects of oleuropein
aglycone; and b.) it should be, at least in part, similar to
that underlying trastuzumab-resistance and "HER2 super-
expression" because co-treatment with oleuropein agly-
cone restored the efficacy of trastuzumab while blocking
up-regulation of HER2 in SKBR3/Tzb100 cells. It has been
reported that oleuropein and β-glucosidase have been
developed as a set to provide a chemical defense against
herbivores or pathogens [71]. Thus, after activation, oleu-
ropein aglycone has strong protein-denaturing/protein-
crosslinking/lysine-decreasing activities, which appear to
be caused by both the glutaraldehyde-like structure
formed after deglucosidation of the iridoid glycoside moi-
ety and the quinone structure formed after oxidation of
the dihydroxy moiety of oleuropein [71]. When we evalu-
ated oleuropein aglycone's metabolism-related anti-
tumoral activity in SKBR3 breast cancer cells, we observed
that oleuropein deglucosidation not only enables its pro-
apoptotic effects but further enhances its anti-HER2
effects (Figure 8, left panel). As suggested above, these find-
ings clearly establish that the interaction with the cell
membrane is a key step regulating the anti-breast cancer
effects of oleuropein aglycone. Moreover, the main
metabolites of oleuropein aglycone (i.e., hydroxytyrosol
and elenolic acid) are not molecularly equivalent in their
ability to diminish HER2 expression (Figure 8, right
panel). Therefore, it is reasonable to suggest that oleuro-
pein aglycone may function, at least in part, through pro-
Relationship between oleuropein metabolism, apoptosis, and HER2 expression in SKBR3 breast cancer cells Figure 8
Relationship between oleuropein metabolism, apoptosis, and HER2 expression in SKBR3 breast cancer cells. In 
order to evaluate how oleuropein aglycone's metabolism affects breast cancer cell viability, breast cancer apoptotic cell death, 
and HER2 oncogene expression, we performed MTT-based metabolic assays (as described in Figure 1), Cell Death ELISAs (as 
described in Figure 2), and HER2-specific ELISAs (as described in Figure 5) in serum-starved SKBR3 cells cultured in the absence 
or presence of equimolar concentrations of oleuropein glycoside (i.e., the precursor form of oleuropein aglycone), oleuropein 
aglycone, hydroxytyrosol (i.e., the dihydroxy moiety of oleuropein aglycone), and elenolic acid (i.e., the iridoid moiety of oleu-
ropein aglycone). Results for HER2 protein expression are means (columns) and 95% confidence intervals (bars) of three inde-
pendent experiments made in triplicate. Statistically significant differences (one-factor ANOVA analysis) between experimental 
conditions and unsupplemented control cells are shown by asterisks (* P < .01, ** P < .001). All statistical tests were two-sided. 
Figure shows both the chemical structures and the metabolic pathway of the EVOO phenolic compounds studied.BMC Cancer 2007, 7:80 http://www.biomedcentral.com/1471-2407/7/80
Page 16 of 19
(page number not for citation purposes)
teasomal degradation of members of the HER family
induced by the quinone structure formed after oxidation
of its dihydroxy moiety, as recently described for other
oleuropein-closely related polyphenols such as apigenin
[74]. On the other hand, treatment with oleuropein agly-
cone failed to modulate the expression levels of HER2-
closely related HER receptors such as HER1 (EGFR), thus
suggesting that oleuropein aglycone may indirectly sup-
press HER2 overexpression at the transcriptional level by
suppressing HER2 promoter activity. We are currently
evaluating whether the inhibitory effects of oleuropein
aglycone on HER2 expression are dependent on the
molecular mechanism eliciting HER2 protein overexpres-
sion in breast cancer cells.
Caution must be applied when extrapolating in vitro
results into clinical practice. Regarding the safety of oleu-
ropein in humans, in acute toxicity studies no lethality or
adverse effects were observed in mice even when it was
administered at doses as high as 1000 mg/kg [73,75].
Moreover, several human studies have been conducted
with olive extracts or its polyphenolics showing no
adverse effects [76-78]. Another important issue is
whether food-derived polyphenols are absorbed and
retain their properties in vivo. A Mediterranean diet rich in
EVOO can supplies ~10–20 mg of polyphenols per day
and, although the bioavailability of different phenolic
compounds varies, it appears that those from EVOO are
well absorbed in humans [69,79]. Also, one limitation of
our current results is that the phenolics that were active
(i.e., oleuropein aglycone) had anti-breast cancer effects at
concentrations that are unlikely to be achieved in vivo.
Considering that plasma concentration of these com-
pounds will exceed 10-6-10-5 M [69,79,80], the tumori-
cidal and anti-HER2 oncogene effects at micromolar
concentrations of oleuropein aglycone are within the con-
centration range expected after nutritional intake from
EVOO-rich Mediterranean diets.
Conclusion
In summary, our findings demonstrate for the first time a
new molecular mechanism by which quantitatively minor
phenolic components of EVOO such as oleuropein agly-
cone, through the specific inhibition of HER2 oncogene,
may exert protective effects not only in the promotion
(risk) but further in the progression (invasion and metas-
tasis) of human breast cancer. Together with EVOO ω-9
MUFA OA, the bitter principle of olives and olive oil oleu-
ropein aglycone is among the first examples of how
selected nutrients from the so-called "Mediterranean
Diet" directly regulate the expression and activity of
HER2, a proto-oncogene that plays a pivotal role in malig-
nant transformation, tumorigenesis, metastasis, and treat-
ment failure in breast cancer disease (Figure 9). The ability
of oleuropein aglycone to exhibit synergistic antitumor
effects when concurrently given to breast cancer cells
chronically exposed to trastuzumab for several months
further underscores the clinical relevance of these findings
as they reveal a novel approach capable to circumvent
trastuzumab resistance in breast cancer disease.
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